Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Total Current Liabilities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Total Current Liabilities for 11 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 17.43% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, down 17.43% year-over-year, with the annual reading at $1.8 billion for FY2025, 17.43% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $1.8 billion at BeOne Medicines, down from $2.4 billion in the prior quarter.
  • The five-year high for Total Current Liabilities was $2.4 billion in Q3 2025, with the low at $917.4 million in Q4 2022.
  • Average Total Current Liabilities over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2021.
  • The sharpest move saw Total Current Liabilities surged 146.25% in 2021, then tumbled 42.65% in 2022.
  • Over 5 years, Total Current Liabilities stood at $1.6 billion in 2021, then crashed by 42.65% to $917.4 million in 2022, then soared by 97.32% to $1.8 billion in 2023, then grew by 22.36% to $2.2 billion in 2024, then fell by 17.43% to $1.8 billion in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $1.8 billion, $2.4 billion, and $2.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.